Key Highlights

  • FY26 Revenue guidance of $105–115 million, reflecting continued underlying growth despite air freight and geopolitical headwinds.
  • Reported EBITDA expected in the range of –$2 million to +$2 million; underlying EBITDA guided at $4–8 million.
  • FDA review progressing to final stages; US store count on track to surpass 10,000 by July 2026.

 

Bubs Australia Limited (ASX:BUB), the infant nutrition company with ambitions to cement itself as a meaningful participant in the United States baby formula market, delivered a trading update on 29 May 2026 that reflects a Business in transition — growing at its core yet absorbing a cluster of external costs that have compressed near-term profitability.

BUB’s share price dropped 2.13% to AUD 0.092 per share at the time of writing on 29 May 2026.

Revenue Trajectory and the Guidance Range

The company guided full-year FY26 revenue to $105–115 million, a range that management characterised as demonstrating underlying growth despite a congested external backdrop. For context, Bubs reported FY25 revenue of approximately $101 million, which means the midpoint of the new guidance — around $110 million — represents roughly 9% year-on-year growth at the Top Line.

That headline figure, however, tells only part of the story. Revenue growth has been accompanied by cost escalation, driven in material part by the company's decision to rely on air freight to re-stock US retail shelves more rapidly than ocean freight would permit. Air freight costs significantly more than sea freight on a per-kilogram basis, and for a company selling competitively priced infant formula in a market where shelf availability is a hygiene Factor for retailer retention, the trade-off appears to have been a deliberate one.

Management indicated that air freight use is concluding as inventory normalises, suggesting that this particular cost overhang is transitional rather than structural — a distinction that investors and analysts will want to track as FY27 progresses.

EBITDA Compression and the Underlying View

The reported EBITDA range of –$2 million to +$2 million places Bubs near breakeven at the statutory level, while the underlying EBITDA guidance of $4–8 million strips out items management regards as non-recurring or externally imposed. The gap between reported and underlying — potentially as wide as $6 million — reflects the scale of the headwinds absorbed during the year.

Among the factors cited: evolving regulatory requirements, product availability constraints, geopolitical disruption in the Middle East affecting trade routes and potentially consumer sentiment in relevant markets, and heightened competitive pressure within the specialty infant formula category. Each of these factors is beyond Bubs' direct control, though the company's ability to manage around them will be a key determinant of its medium-term Earnings profile.

The US Market: Scale Ambition and Execution Risk

The United States remains the centrepiece of Bubs' growth strategy. CEO Joe Coote specifically noted the company is on track to achieve ranging across more than 10,000 stores by July 2026 — a milestone that would represent a significant step-change in US distribution breadth. For comparison, national US retailers typically operate between 1,500 and 5,000 locations, meaning a 10,000-store network implies a multi-retailer footprint across mainstream and specialty channels.

Reaching shelf space and maintaining it are distinct challenges. Bubs gained US market presence in part through the emergency infant formula access program that the FDA facilitated in 2022 following widespread domestic Supply disruptions. Sustaining and growing that position now requires competing on price, quality, availability, and Marketing Investment against both domestic incumbents and other international entrants.

Encouragingly, Coote noted that FDA engagement remains positive and the review is progressing toward its final stages. Successful completion of that process would remove a residual regulatory overhang and potentially unlock broader commercial access within US federal nutrition programs — a material prize for any formula Brand.

Balance Sheet Discipline and Strategic Positioning

Bubs indicated it maintains a sound balance sheet with adequate Liquidity, enabling the company to absorb near-term cost pressures without materially compromising its strategic agenda. Capital discipline has become a recurring theme in Bubs' communications, reflecting lessons learned from a period of rapid international expansion that stretched resources in prior years.

The company's current focus appears to be on converting demonstrated consumer Demand — which management characterised as intact — into sustainable revenue by expanding distribution and continuing investment in brand activation. Those two levers, distribution reach and brand salience, are precisely the ones that determine whether a premium infant formula brand can achieve durable market position in the highly competitive US mass market.

Conclusion

Bubs Australia's FY26 trading update presents a picture of a company that has prioritised distribution scale and market access over near-term Margin, absorbing meaningful one-off costs to position itself for a larger commercial footprint. The 10,000-store milestone in the US, the FDA review nearing conclusion, and the wind-down of air freight costs all point toward an anticipated improvement in FY27 earnings quality. Whether the underlying demand that management describes converts into the kind of top-line growth that can justify the near-term investment remains the central question for investors tracking this stock.